摘要:
The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Cyclin Dependent kinase inhibitors (CDKi), methods of determining the sensitivity of a cell to a CDKi, methods of treating a patient with a CDKi and methods of screening for candidate CDKi.
摘要:
This invention relates to compounds of the formula (I) wherein the variable substituents are described herein. The compounds are useful for the treatment of conditions and diseases characterized by an aberrant MAP kinase signaling pathway, such as cancer.
摘要:
The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.
摘要:
Provided are an anode for a battery comprising: (a) an anode active material, (b) TiO2, and (c) a styrene-butadiene rubber (SBR), and a lithium secondary battery comprising the same. By using titanium oxide and SBR together with an anode active material as the anode components in the present invention, increase in the anode resistivity during the high-temperature storage and reduction in the battery capacity by the resistivity are inhibited, thereby the overall performances of the battery can be improved.
摘要:
Disclosed herein is a cathode active material for a secondary battery, which includes a combination of one or more selected from compounds represented by Formula 1, one or more selected from compounds represented by Formula 2, and one or more selected from compounds represented by Formula 3, (1-s-t)[Li(LiaMn(1-a-x-y)NixCoy)O2]*s[Li2CO3]*t[LiOH] (1) Li(LibMn(2-b)O4 (2) (1-u)LiFePO4*uC (3) In these formulae 0 y>0.6; 0
摘要翻译:本文公开了一种二次电池用正极活性物质,它包括一种或多种选自式1表示的化合物,一种或多种选自式2化合物的化合物和选自由式3表示的化合物的一种或多种 ,(1-st)[Li(LiaMn(1-axy)NixCoy)O 2] * s [Li 2 CO 3] * t [LiOH](1)Li(LibMn(2-b)O4(2) * uC(3)在这些公式中0 y> 0.6; 0